About Careers Internship MedBlog Contact us

Thailand HIV Vaccine Study Sheds More Light on Limited Protection Provided by HIV Vaccines

by Kathy Jones on May 9, 2013 at 8:18 PM
 Thailand HIV Vaccine Study Sheds More Light on Limited Protection Provided by HIV Vaccines

The ongoing HIV vaccine trial currently being conducted in Thailand is shedding more light on how immune responses were triggered and why the vaccine is not effective in more people.

In a study appearing May 6, 2013, in the journal Proceedings of the National Academy of Sciences, an international team of researchers led by the Duke Human Vaccine Institute describe a previously unknown interaction between antibodies that worked to block the vaccine's protective powers.


The vaccine trial, known as RV144, used two investigational vaccines in combination, resulting in an unprecedented 31 percent protection rate among participants. While encouraging, that rate fell short of the minimum needed for public health use. However, additional analyses of the trial's data are yielding a trove of information about the virus and its potential vulnerabilities.

Last year, Duke researchers published a study in the New England Journal of Medicine that detailed clues to why the vaccine tested in the RV144 trial protected some volunteers.

In the current analysis, study authors, led by Georgia D. Tomaras, PhD, director of the Laboratory of Immune Responses and Virology at DHVI, explored the inverse relationship that helps explain why the vaccine may have failed to protect more of the participants.

"We learned that a specific vaccine-induced immunoglobulin A can weaken the protective effect of immunoglobulin G. IgA competes with IgG to bind to the same site on the virus's outer envelope that is exposed on infected cells," Tomaras said. "In work with my colleague here at Duke, Dr. Guido Ferrari, we found that the IgA antibodies can block the activity of natural killer cells activated by IgG, further interfering with the vaccine-induced immune response."

Tomaras added that decreased vaccine effect was higher among participants who had more specific immunoglobulin A evident in blood samples compared to immunoglobulin G, suggesting that the ratio of virus-specific IgA to IgG in blood may be an important marker for vaccine effectiveness.

"Understanding that certain vaccine-induced immunoglobulin A antibodies in the blood may interfere with an antiviral function of another antibody is a new finding that can lead to further vaccine development on how to induce effective antibody responses," Tomaras said.

In addition to Tomaras, study authors at Duke include Guido Ferrari, Xiaoying Shen, S. Munir Alam, Hua-Xin Liao, Justin Pollara, Mattia Bonsignori, M. Anthony Moody, Xi Chen, Brigid Poling, Cindo O. Nicholson, Ruijun Zhang, Xiaozhi Lu, Robert Parks, David C. Montefiori and Barton F. Haynes; along with Youyi Fong and Peter B. Gilbert of the Statistical Center for HIV/AIDS Research & Prevention; Jaranit Kaewkungwal and Punnee Pitisuttithum of Mahidol University, Thailand; Sorachai Nitayaphan of Armed Forces Research Institute of Medical Sciences, Thailand; Supachai Rerks-Ngarm of the Department of Disease Control, Ministry of Public Health, Thailand; and Jerome H. Kim and Nelson L. Michael of the U.S. Military HIV Research Program.

The work was supported in part by the Bill & Melinda Gates Foundation; the National Institutes of Health, National Institute of Allergy and Infectious Diseases (U01 AI067854, 5U01 AI46725-05); an interagency agreement between the U.S. Army Medical Research and Material Command and the NIAID (Y1AI-2642-12); and a cooperative agreement with the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (Y1AI-2642-12).

A full listing of research support is provided in the study manuscript.

Source: Newswise
Font : A-A+



Recommended Readings

Latest AIDS/HIV News

HIV Vaccine Clinical Trial Initiates in the United States and South Africa
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
Beauty Salon-Driven Initiative Boosts PrEP Awareness in Fight Against AIDS
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Immune-Evading HIV Protein Complex Solved
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Does Gender Influence Comorbidity Rates in HIV-Positive Smokers
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
Digital Test Measures HIV Viral Load
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Thailand HIV Vaccine Study Sheds More Light on Limited Protection Provided by HIV Vaccines Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests